恩格列净、利拉鲁肽和二甲双胍治疗新发2型糖尿病合并NAFLD患者的效果  

Effectiveness of Empagliflozin,Liraglutide and Metformin in the Treatment of Patients with New-onset Type 2 Diabetes Mellitus Combined with NAFLD

作　　者：陈玉珠[1] CHEN Yuzhu(Department of Endocrinology,Fuding Hospital,Ningde,Fujian Province,355200 China)

机构地区：[1]福建省福鼎市医院内分泌科,福建宁德355200

出　　处：《糖尿病新世界》2022年第20期110-112,171,共4页Diabetes New World Magazine

摘　　要：目的探究在新发2型糖尿病合并非酒精性脂肪肝(non-alcoholic fatty liver disease,NAFLD)患者的临床治疗中,恩格列净、利拉鲁肽和二甲双胍的应用效果。方法随机选取2020年5月—2021年10月福建省福鼎市医院收治的2型糖尿病合并非酒精性脂肪肝患者84例,以数字表法分为恩格列净组、利拉鲁肽组和二甲双胍组,各28例,比较3组患者治疗前后血糖、血脂指标以及肝功能指标。结果治疗前,3组患者血脂、血糖指标及肝功能比较,差异无统计学意义(P>0.05);治疗后,所有患者情况均有改善,恩格列净组与利拉鲁肽组血糖水平差异无统计学意义(P>0.05),恩格列净组与利拉鲁肽组血糖水平显著低于二甲双胍组,差异有统计学意义(P<0.05);利拉鲁肽组LDL-C与TC指标改善幅度大于恩格列净组与二甲双胍组,差异有统计学意义(P<0.05);恩格列净组与利拉鲁肽组肝功能指标差异无统计学意义(P>0.05),恩格列净组与利拉鲁肽组肝功能改善效果明显优于二甲双胍组,差异有统计学意义(P<0.05)。结论在新发2型糖尿病合并NAFLD患者的治疗中,恩格列净与利拉鲁肽疗效均优于二甲双胍,能够有效改善患者血糖血脂指标、提升肝功能,但在血脂改善方面,利拉鲁肽效果更佳。Objective To investigate the effects of empagliflozin,liraglutide and metformin in the clinical treatment of patients with new-onset type 2 diabetes mellitus combined with non-alcoholic fatty liver disease(NAFLD).Methods 84 cases patients of type 2 diabetes mellitus combined with non-alcoholic fatty liver disease(NAFLD)admitted to Fuding Hospital in Fujian Province from May 2020 to October 2021 were randomly selected and divided into the empagliflozin group,liraglutide group and metformin group by numerical table method,28 cases in each,to compare the blood glucose and blood lipid indexes and liver function indexes before and after treatment in the three groups.Results Before treatment,there were no statistically significant differences in lipid and blood glucose indexes and liver function in the three groups(P>0.05);after treatment,all patients improved,there was no statistically significant difference in blood glucose levels between the empagliflozin group and liraglutide groups(P>0.05),and the blood glucose levels in the empagliflozin group and liraglutide groups were significantly lower than those in the metformin group,the difference was statistically significant(P<0.05).The improvement of LDL-C and TC indexes in the liraglutide group was greater than that in the empagliflozin group and metformin group,the difference was statistically significant(P<0.05).There was no statistically significant difference in liver function between the empagliflozin group and liraglutide groups(P>0.05),and the improvement of liver function in the empagliflozin group and liraglutide groups was significantly better than that in the metformin group,and the difference was statistically significant(P<0.05).Conclusion In the treatment of patients with new-onset type 2 diabetes combined with NAFLD,the efficacy of both empagliflozin and liraglutide is better than that of metformin,and they can effectively improve patients’glucose and lipid indexes and liver function,but liraglutide is more effective in the improvement of lipid profil

关 键 词：恩格列净 利拉鲁肽 二甲双胍 2型糖尿病 NAFLD 

分 类 号：R58[医药卫生—内分泌]